Vivus Wins Its First Fda Drug Approval

The FDA approved a drug to treat erectile dysfunction from Vivus that would compete against Viagra, Cialis and Levitra.

Topics:  fda   vivus   viagra   cialis   levitra   drug   
BING NEWS:
  • Vivus Wins US Approval to Sell New Diet Drug Qsymia
    Vivus also must perform post-approval safety studies, including research to assess cardiovascular risk of taking the diet drug. Last month, the FDA approved Arena's diet pill Belviq for sale in the US, making it the first new weight loss drug approved in ...
    07/18/2012 - 1:29 am | View Link
  • Vivus Wins FDA Approval for Obesity Drug, After Long, Messy Day
    Vivus has been pushing for more than two years to get its new obesity drug cleared for sale by the FDA, and after one last long, confusing day, it finally got its wish. The FDA said today that the Mountain View, CA-based company (NASDAQ: VVUS) has gotten ...
    07/17/2012 - 12:32 pm | View Link
  • Vivus Wins FDA Approval
    MINYANVILLE ORIGINAL Vivus (VVUS) shareholders got a piece of good news late last week when the Food and Drug Administration approved the ... a decision on market clearance in April but the FDA delayed doing so until July 17. "The majority of the value ...
    04/30/2012 - 9:07 am | View Link
  • Vivus' Erectile Dysfunction Drug Stendra Wins FDA Approval
    Law360, New York (April 27, 2012, 8:00 PM ET) -- The U.S. Food and Drug Administration on Friday approved Vivus Inc.'s erectile dysfunction pill Stendra, the first erectile dysfunction treatment to be allowed for use in the U.S. in a decade and the first ...
    04/27/2012 - 1:00 pm | View Link
  • Vivus Obesity Pill Wins FDA Panel Nod; NeuroSearch Surges
    Trading in Vivus stock was halted yesterday before the FDA panel vote. NeuroSearch, which is developing tesofensine for obesity, climbed 5.6 percent to 17 kroner and Novo Nordisk, which is studying its Victoza diabetes drug as a weight-loss treatment ...
    02/22/2012 - 11:00 am | View Link
  • More
BING SEARCH:
  • VVUS
    Up to date analysis of Vivus, Inc. (VVUS) and its stock by hedge fund managers and industry experts. Find out what Vivus, Inc. is saying about its business from the ...
    08/1/2014 - 4:05 pm | View Website
  • Homepage
    The Burrill Report ... By the numbers Sage Therapeutics Scores $90M in Upsized IPO. At a time when many biotech stocks fell on Federal Reserve Chairwoman Janet Yellen ...
    08/1/2014 - 3:15 pm | View Website
  • FDA's Top Q4 Blockbuster Drug Decisions
    The FDA has some of its biggest decisions of the year looming in the next few months. The first new lupus drug in half a century, a blood-thinner with mega ...
    08/1/2014 - 7:23 am | View Website
  • BioWorld | The Daily Biopharmaceutical News Source
    Contains business, science, and regulatory news, including mergers and collaborations, FDA hearings and results, and research breakthroughs. Need subscription to use.
    08/1/2014 - 4:10 am | View Website
  • VIVUS Qsymia Patents: Intellectual Property House of Cards ...
    Robert Diggs Deeper: Is Vivus Worth more than $0.24 Per Share? What is new in the report? A prior art challenge I filed against a pending Qsymia patent in ...
    07/28/2014 - 5:19 am | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More U.s. News